Updated Drug Labeling for Patient Safety Act

Bill: 117-hr-9011
Sponsor: full_name: Rep. McEachin, A. Donald [D-VA-4]
Introduced: 2022-09-28
Policy area: Health
Subjects: Administrative law and regulatory procedures

Department of Health and Human Services

Drug safety, medical device, and laboratory regulation

Prescription drugs
Latest action: action_date: 2022-09-29
text: Referred to the Subcommittee on Health.

Summaries:
action_date: 2022-09-28
action_desc: Introduced in House
text: <p><b>Updated Drug Labeling for Patient Safety Act</b></p> <p>This bill allows generic drug manufacturers to revise labels with updated safety information that differs from the referenced brand-name drug.</p>

tv_txt: I 117th CONGRESS 2d Session H. R. 9011 IN THE HOUSE OF REPRESENTATIVES September 28, 2022 Mr. McEachin introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To amend the Federal Food, Drug, and Cosmetic Act to direct the Secretary of Health and Human Services to establish a process to allow the holders of abbreviated new drug applications to make labeling changes to include new or updated safety-related information, and for other purposes.

1. Short title This Act may be cited as the Updated Drug Labeling for Patient Safety Act . 2. Safety labeling changes initiated by ANDA holders (a) In general Section 505(j) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355(j) ) is amended by adding at the end the following: (14) Notwithstanding paragraphs (2)(A)(v), the Secretary shall establish a process to allow the holder of an abbreviated new drug application to change the labeling of the drug that is the subject of the application to include new or updated safety-related information, including a process to make such changes prior to being approved by the Secretary. . (b) Regulations (1) In general Not later than 18 months after the date of enactment of this Act, the Secretary of Health and Human Services shall issue a final rule to implement paragraph (14) of section 505(j) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355(j) ), as added by subsection (a). (2) Contents The final rule issued under paragraph (1) shall include a process for conforming the labeling of a drug that is labeled pursuant to such paragraph (14), the listed drug (as such term is used in such section 505(j)), and other drugs approved under such section 505(j) that reference such listed drug. (3) Effective date The final rule issued under paragraph (1) shall become effective not later than 180 days after the date on which such final rule is issued.